Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/2 trial evaluating ABCL635.

AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause.

New data show a single dose of AbCellera's menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.

AbCellera ‌said Monday its experimental menopause treatment significantly reduced the ​frequency and severity ​of hot flashes in a ⁠mid-stage trial, sending its ​shares up 24% in ​premarket trading.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Aug. 10, 2026.